These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

377 related articles for article (PubMed ID: 30848854)

  • 41. Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study.
    Luchetti MM; Benfaremo D; Ciccia F; Bolognini L; Ciferri M; Farinelli A; Rossini M; Mosca P; Triolo G; Gabrielli A
    World J Gastroenterol; 2017 Oct; 23(39):7139-7149. PubMed ID: 29093622
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Familial occurrence and inheritance studies in inflammatory bowel disease.
    Binder V; Orholm M
    Neth J Med; 1996 Feb; 48(2):53-6. PubMed ID: 8819799
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety of anti-tumor necrosis factor therapy during pregnancy in patients with inflammatory bowel disease.
    Androulakis I; Zavos C; Christopoulos P; Mastorakos G; Gazouli M
    World J Gastroenterol; 2015 Dec; 21(47):13205-11. PubMed ID: 26715803
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Ten missteps in the management of inflammatory bowel disease in Asia: An expert report by the Asian Pacific Association of Gastroenterology Working Group on Inflammatory Bowel Disease.
    Ahuja V; Hilmi I; Ye BD; Ling KL; Ng SC; Leong RW; Kumar P; Khoo XH; Makharia GK; Sollano J; Pisespongsa P; Mustaffa N; Banerjee R; Leow AH; Raja Ali RA; Chuah SW; Palaniappan S; Ooi CJ; Leung WK
    J Gastroenterol Hepatol; 2024 Aug; 39(8):1500-1508. PubMed ID: 38725188
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The Asia-Pacific consensus on ulcerative colitis.
    Ooi CJ; Fock KM; Makharia GK; Goh KL; Ling KL; Hilmi I; Lim WC; Kelvin T; Gibson PR; Gearry RB; Ouyang Q; Sollano J; Manatsathit S; Rerknimitr R; Wei SC; Leung WK; de Silva HJ; Leong RW;
    J Gastroenterol Hepatol; 2010 Mar; 25(3):453-68. PubMed ID: 20370724
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Inflammatory bowel disease. Part I: Nature and pathogenesis.
    Kirsner JB
    Dis Mon; 1991 Oct; 37(10):605-66. PubMed ID: 1893828
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Biosimilars in Inflammatory Bowel Disease - Accumulating Clinical Evidence.
    McConachie S; Wilhelm SM; Kale-Pradhan PB
    Expert Rev Clin Pharmacol; 2017 Apr; 10(4):391-400. PubMed ID: 28095262
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Infliximab Is Not Associated With Increased Risk of Malignancy or Hemophagocytic Lymphohistiocytosis in Pediatric Patients With Inflammatory Bowel Disease.
    Hyams JS; Dubinsky MC; Baldassano RN; Colletti RB; Cucchiara S; Escher J; Faubion W; Fell J; Gold BD; Griffiths A; Koletzko S; Kugathasan S; Markowitz J; Ruemmele FM; Veereman G; Winter H; Masel N; Shin CR; Tang KL; Thayu M
    Gastroenterology; 2017 Jun; 152(8):1901-1914.e3. PubMed ID: 28193515
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study.
    Casanova MJ; Chaparro M; García-Sánchez V; Nantes O; Leo E; Rojas-Feria M; Jauregui-Amezaga A; García-López S; Huguet JM; Arguelles-Arias F; Aicart M; Marín-Jiménez I; Gómez-García M; Muñoz F; Esteve M; Bujanda L; Cortés X; Tosca J; Pineda JR; Mañosa M; Llaó J; Guardiola J; Pérez-Martínez I; Muñoz C; González-Lama Y; Hinojosa J; Vázquez JM; Martinez-Montiel MP; Rodríguez GE; Pajares R; García-Sepulcre MF; Hernández-Martínez A; Pérez-Calle JL; Beltrán B; Busquets D; Ramos L; Bermejo F; Barrio J; Barreiro-de Acosta M; Roncedo O; Calvet X; Hervías D; Gomollón F; Domínguez-Antonaya M; Alcaín G; Sicilia B; Dueñas C; Gutiérrez A; Lorente-Poyatos R; Domínguez M; Khorrami S; Muñoz C; Taxonera C; Rodríguez-Pérez A; Ponferrada A; Van Domselaar M; Arias-Rivera ML; Merino O; Castro E; Marrero JM; Martín-Arranz M; Botella B; Fernández-Salazar L; Monfort D; Opio V; García-Herola A; Menacho M; Ramírez-de la Piscina P; Ceballos D; Almela P; Navarro-Llavat M; Robles-Alonso V; Vega-López AB; Moraleja I; Novella MT; Castaño-Milla C; Sánchez-Torres A; Benítez JM; Rodríguez C; Castro L; Garrido E; Domènech E; García-Planella E; Gisbert JP
    Am J Gastroenterol; 2017 Jan; 112(1):120-131. PubMed ID: 27958281
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Asian perspectives in the management of inflammatory bowel disease: findings from a recent survey.
    Sung JJ; Kamm MA; Marteau P
    J Gastroenterol Hepatol; 2010 Jan; 25(1):183-93. PubMed ID: 19929931
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Asian Organization for Crohn's and Colitis and Asian Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: Risk assessment.
    Park DI; Hisamatsu T; Chen M; Ng SC; Ooi CJ; Wei SC; Banerjee R; Hilmi IN; Jeen YT; Han DS; Kim HJ; Ran Z; Wu K; Qian J; Hu PJ; Matsuoka K; Andoh A; Suzuki Y; Sugano K; Watanabe M; Hibi T; Puri AS; Yang SK
    J Gastroenterol Hepatol; 2018 Jan; 33(1):20-29. PubMed ID: 29023903
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Treatment of colitis ulcerosa and Crohn's disease].
    Kovács A
    Orv Hetil; 2006 Apr; 147(16):755-8. PubMed ID: 16711262
    [No Abstract]   [Full Text] [Related]  

  • 53. Incidence and Clinical Outcomes of Inflammatory Bowel Disease in South Korea, 2011-2014: A Nationwide Population-Based Study.
    Jung YS; Han M; Kim WH; Park S; Cheon JH
    Dig Dis Sci; 2017 Aug; 62(8):2102-2112. PubMed ID: 28593437
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Low prevalence of CMV infection in patients with Crohn's disease in comparison with ulcerative colitis: effect of different immune response on prevalence of CMV infection.
    Nakase H; Yoshino T; Honzawa Y; Chiba T
    Dig Dis Sci; 2010 May; 55(5):1498-9. PubMed ID: 20198427
    [No Abstract]   [Full Text] [Related]  

  • 55. Generalized Pyoderma Gangrenosum Associated with Ulcerative Colitis: Successful Treatment with Infliximab and Azathioprine.
    Chatzinasiou F; Polymeros D; Panagiotou M; Theodoropoulos K; Rigopoulos D
    Acta Dermatovenerol Croat; 2016 Apr; 24(1):83-5. PubMed ID: 27149138
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Delay in prior authorization of biologic therapy: Another possible cause of healthcare disparity in IBD patients.
    Rao V; Dharia I; Gibilisco J; Kirelik D; Baumgartner S; Negreira K; Chawla K; Dave J; Kallus S; Belfaqeeh OA; Borum ML
    J Natl Med Assoc; 2024 Feb; 116(1):13-15. PubMed ID: 38036315
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and Crohn's disease).
    Ferrante M; D'Haens G; Rutgeerts P; Vermeire S; Van Assche G
    Curr Gastroenterol Rep; 2009 Dec; 11(6):504-8. PubMed ID: 19903427
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of a prodromal period in Crohn's disease but not ulcerative colitis.
    Pimentel M; Chang M; Chow EJ; Tabibzadeh S; Kirit-Kiriak V; Targan SR; Lin HC
    Am J Gastroenterol; 2000 Dec; 95(12):3458-62. PubMed ID: 11151877
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Anti-TNF biologics in the treatment of chronic inflammatory bowel disease].
    Nikolaus S; Schreiber S
    Internist (Berl); 2008 Aug; 49(8):947-8, 950-3. PubMed ID: 18584139
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Biologic Agents Are Associated with Excessive Weight Gain in Children with Inflammatory Bowel Disease.
    Haas L; Chevalier R; Major BT; Enders F; Kumar S; Tung J
    Dig Dis Sci; 2017 Nov; 62(11):3110-3116. PubMed ID: 28895012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.